Role of Soluble ST2 Biomarker in Predicting Recurrence of Atrial Fibrillation after Electrical Cardioversion or Pulmonary Vein Isolation
This study aims to determine the predictive value of the soluble suppression of tumorigenicity 2 (sST2) biomarker in atrial fibrillation (AF) recurrence. This prospective, observational study included patients with AF referred for electrical cardioversion (ECV) or pulmonary vein isolation (PVI) proc...
| Main Authors: | , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-09-01
|
| Series: | International Journal of Molecular Sciences |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1422-0067/24/18/14045 |
| _version_ | 1797579659923161088 |
|---|---|
| author | Javier García-Seara Laila González Melchor Javier Rodríguez García Francisco Gude José Luis Martínez Sande Moisés Rodríguez Mañero Xesús Alberte Fernández López Carlos Minguito Carazo Teba González Ferrero Sonia Eiras Ricardo Lage Isabel Moscoso Sandra Feijoo Bandín Francisca Lago Ezequiel Alvarez Clara V. Alvarez José Ramón González Juanatey |
| author_facet | Javier García-Seara Laila González Melchor Javier Rodríguez García Francisco Gude José Luis Martínez Sande Moisés Rodríguez Mañero Xesús Alberte Fernández López Carlos Minguito Carazo Teba González Ferrero Sonia Eiras Ricardo Lage Isabel Moscoso Sandra Feijoo Bandín Francisca Lago Ezequiel Alvarez Clara V. Alvarez José Ramón González Juanatey |
| author_sort | Javier García-Seara |
| collection | DOAJ |
| description | This study aims to determine the predictive value of the soluble suppression of tumorigenicity 2 (sST2) biomarker in atrial fibrillation (AF) recurrence. This prospective, observational study included patients with AF referred for electrical cardioversion (ECV) or pulmonary vein isolation (PVI) procedures. Baseline characteristics were collected, and sST2 was determined at baseline and at 3 and 6 months of follow-up. sST2 was determined at baseline in a matched control group. Left atrial voltage mapping was performed in patients undergoing PVI. The sST2 maximal predictive capacity of AF recurrence was at the 3-month FU in the cohort of patients undergoing ECV with respect to 6-month AF recurrence with an AUC of 0.669, a cut-off point of 15,511 pg/mL, a sensitivity of 60.97%, and a specificity of 69.81%. The ROC curve of the sST2 biomarker at baseline and 3 months in the cohort of patients undergoing PVI showed AUCs of 0.539 and 0.490, respectively. The logistic regression model identified the rhythm (AF) and the sST2 biomarker at 3 months as independent factors for recurrence at 6 months in the ECV cohort. In the logistic regression model, sST2 was not an independent factor for recurrence at 6 months of follow-up in the PVI cohort. In patients who underwent ECV, sST2 values at 3 months may provide utility to predict AF recurrence at 6 months of follow-up. In patients who underwent PVI, sST2 had no value in predicting AF recurrence at 6 months of follow-up. |
| first_indexed | 2024-03-10T22:40:20Z |
| format | Article |
| id | doaj.art-6a583a33f9494736a0328bf7da10ef07 |
| institution | Directory Open Access Journal |
| issn | 1661-6596 1422-0067 |
| language | English |
| last_indexed | 2024-03-10T22:40:20Z |
| publishDate | 2023-09-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | International Journal of Molecular Sciences |
| spelling | doaj.art-6a583a33f9494736a0328bf7da10ef072023-11-19T11:07:03ZengMDPI AGInternational Journal of Molecular Sciences1661-65961422-00672023-09-0124181404510.3390/ijms241814045Role of Soluble ST2 Biomarker in Predicting Recurrence of Atrial Fibrillation after Electrical Cardioversion or Pulmonary Vein IsolationJavier García-Seara0Laila González Melchor1Javier Rodríguez García2Francisco Gude3José Luis Martínez Sande4Moisés Rodríguez Mañero5Xesús Alberte Fernández López6Carlos Minguito Carazo7Teba González Ferrero8Sonia Eiras9Ricardo Lage10Isabel Moscoso11Sandra Feijoo Bandín12Francisca Lago13Ezequiel Alvarez14Clara V. Alvarez15José Ramón González Juanatey16Cardiology Department, University Clinical Hospital of Santiago de Compostela, 15706 Santiago de Compostela, SpainCardiology Department, University Clinical Hospital of Santiago de Compostela, 15706 Santiago de Compostela, SpainClinical Analysis Department, University Clinical Hospital of Santiago de Compostela, 15706 Santiago de Compostela, SpainInstitute of Biomedical Research of Santiago de Compostela (IDIS-SERGAS), Travesía da Choupana s/n, 15706 Santiago de Compostela, SpainCardiology Department, University Clinical Hospital of Santiago de Compostela, 15706 Santiago de Compostela, SpainCardiology Department, University Clinical Hospital of Santiago de Compostela, 15706 Santiago de Compostela, SpainCardiology Department, University Clinical Hospital of Santiago de Compostela, 15706 Santiago de Compostela, SpainCardiology Department, University Clinical Hospital of Santiago de Compostela, 15706 Santiago de Compostela, SpainCardiology Department, University Clinical Hospital of Santiago de Compostela, 15706 Santiago de Compostela, SpainCentro de Investigación Biomédica Cardiovascular en Red (CIBERCV), Institute of Health Carlos III, C/Monforte de Lemos 3-5, Pabellón 11, Planta 0, 28029 Madrid, SpainCentro de Investigación Biomédica Cardiovascular en Red (CIBERCV), Institute of Health Carlos III, C/Monforte de Lemos 3-5, Pabellón 11, Planta 0, 28029 Madrid, SpainCentro de Investigación Biomédica Cardiovascular en Red (CIBERCV), Institute of Health Carlos III, C/Monforte de Lemos 3-5, Pabellón 11, Planta 0, 28029 Madrid, SpainCentro de Investigación Biomédica Cardiovascular en Red (CIBERCV), Institute of Health Carlos III, C/Monforte de Lemos 3-5, Pabellón 11, Planta 0, 28029 Madrid, SpainCentro de Investigación Biomédica Cardiovascular en Red (CIBERCV), Institute of Health Carlos III, C/Monforte de Lemos 3-5, Pabellón 11, Planta 0, 28029 Madrid, SpainDepartment of Pharmacology, Pharmacy and Pharmaceutical Technology, University of Santiago de Compostela, 15782 Santiago de Compostela, SpainNeoplasia & Endocrine Differentiation, Centro de Investigación en Medicina Molecular y Enfermedades Crónicas (CIMUS), University of Santiago de Compostela, Instituto de Investigación Sanitaria (IDIS), 15782 Santiago de Compostela, SpainCardiology Department, University Clinical Hospital of Santiago de Compostela, 15706 Santiago de Compostela, SpainThis study aims to determine the predictive value of the soluble suppression of tumorigenicity 2 (sST2) biomarker in atrial fibrillation (AF) recurrence. This prospective, observational study included patients with AF referred for electrical cardioversion (ECV) or pulmonary vein isolation (PVI) procedures. Baseline characteristics were collected, and sST2 was determined at baseline and at 3 and 6 months of follow-up. sST2 was determined at baseline in a matched control group. Left atrial voltage mapping was performed in patients undergoing PVI. The sST2 maximal predictive capacity of AF recurrence was at the 3-month FU in the cohort of patients undergoing ECV with respect to 6-month AF recurrence with an AUC of 0.669, a cut-off point of 15,511 pg/mL, a sensitivity of 60.97%, and a specificity of 69.81%. The ROC curve of the sST2 biomarker at baseline and 3 months in the cohort of patients undergoing PVI showed AUCs of 0.539 and 0.490, respectively. The logistic regression model identified the rhythm (AF) and the sST2 biomarker at 3 months as independent factors for recurrence at 6 months in the ECV cohort. In the logistic regression model, sST2 was not an independent factor for recurrence at 6 months of follow-up in the PVI cohort. In patients who underwent ECV, sST2 values at 3 months may provide utility to predict AF recurrence at 6 months of follow-up. In patients who underwent PVI, sST2 had no value in predicting AF recurrence at 6 months of follow-up.https://www.mdpi.com/1422-0067/24/18/14045soluble suppression of tumorigenicity 2 (sST2)atrial fibrillationelectrical cardioversionpulmonary vein ablation |
| spellingShingle | Javier García-Seara Laila González Melchor Javier Rodríguez García Francisco Gude José Luis Martínez Sande Moisés Rodríguez Mañero Xesús Alberte Fernández López Carlos Minguito Carazo Teba González Ferrero Sonia Eiras Ricardo Lage Isabel Moscoso Sandra Feijoo Bandín Francisca Lago Ezequiel Alvarez Clara V. Alvarez José Ramón González Juanatey Role of Soluble ST2 Biomarker in Predicting Recurrence of Atrial Fibrillation after Electrical Cardioversion or Pulmonary Vein Isolation International Journal of Molecular Sciences soluble suppression of tumorigenicity 2 (sST2) atrial fibrillation electrical cardioversion pulmonary vein ablation |
| title | Role of Soluble ST2 Biomarker in Predicting Recurrence of Atrial Fibrillation after Electrical Cardioversion or Pulmonary Vein Isolation |
| title_full | Role of Soluble ST2 Biomarker in Predicting Recurrence of Atrial Fibrillation after Electrical Cardioversion or Pulmonary Vein Isolation |
| title_fullStr | Role of Soluble ST2 Biomarker in Predicting Recurrence of Atrial Fibrillation after Electrical Cardioversion or Pulmonary Vein Isolation |
| title_full_unstemmed | Role of Soluble ST2 Biomarker in Predicting Recurrence of Atrial Fibrillation after Electrical Cardioversion or Pulmonary Vein Isolation |
| title_short | Role of Soluble ST2 Biomarker in Predicting Recurrence of Atrial Fibrillation after Electrical Cardioversion or Pulmonary Vein Isolation |
| title_sort | role of soluble st2 biomarker in predicting recurrence of atrial fibrillation after electrical cardioversion or pulmonary vein isolation |
| topic | soluble suppression of tumorigenicity 2 (sST2) atrial fibrillation electrical cardioversion pulmonary vein ablation |
| url | https://www.mdpi.com/1422-0067/24/18/14045 |
| work_keys_str_mv | AT javiergarciaseara roleofsolublest2biomarkerinpredictingrecurrenceofatrialfibrillationafterelectricalcardioversionorpulmonaryveinisolation AT lailagonzalezmelchor roleofsolublest2biomarkerinpredictingrecurrenceofatrialfibrillationafterelectricalcardioversionorpulmonaryveinisolation AT javierrodriguezgarcia roleofsolublest2biomarkerinpredictingrecurrenceofatrialfibrillationafterelectricalcardioversionorpulmonaryveinisolation AT franciscogude roleofsolublest2biomarkerinpredictingrecurrenceofatrialfibrillationafterelectricalcardioversionorpulmonaryveinisolation AT joseluismartinezsande roleofsolublest2biomarkerinpredictingrecurrenceofatrialfibrillationafterelectricalcardioversionorpulmonaryveinisolation AT moisesrodriguezmanero roleofsolublest2biomarkerinpredictingrecurrenceofatrialfibrillationafterelectricalcardioversionorpulmonaryveinisolation AT xesusalbertefernandezlopez roleofsolublest2biomarkerinpredictingrecurrenceofatrialfibrillationafterelectricalcardioversionorpulmonaryveinisolation AT carlosminguitocarazo roleofsolublest2biomarkerinpredictingrecurrenceofatrialfibrillationafterelectricalcardioversionorpulmonaryveinisolation AT tebagonzalezferrero roleofsolublest2biomarkerinpredictingrecurrenceofatrialfibrillationafterelectricalcardioversionorpulmonaryveinisolation AT soniaeiras roleofsolublest2biomarkerinpredictingrecurrenceofatrialfibrillationafterelectricalcardioversionorpulmonaryveinisolation AT ricardolage roleofsolublest2biomarkerinpredictingrecurrenceofatrialfibrillationafterelectricalcardioversionorpulmonaryveinisolation AT isabelmoscoso roleofsolublest2biomarkerinpredictingrecurrenceofatrialfibrillationafterelectricalcardioversionorpulmonaryveinisolation AT sandrafeijoobandin roleofsolublest2biomarkerinpredictingrecurrenceofatrialfibrillationafterelectricalcardioversionorpulmonaryveinisolation AT franciscalago roleofsolublest2biomarkerinpredictingrecurrenceofatrialfibrillationafterelectricalcardioversionorpulmonaryveinisolation AT ezequielalvarez roleofsolublest2biomarkerinpredictingrecurrenceofatrialfibrillationafterelectricalcardioversionorpulmonaryveinisolation AT claravalvarez roleofsolublest2biomarkerinpredictingrecurrenceofatrialfibrillationafterelectricalcardioversionorpulmonaryveinisolation AT joseramongonzalezjuanatey roleofsolublest2biomarkerinpredictingrecurrenceofatrialfibrillationafterelectricalcardioversionorpulmonaryveinisolation |